Glaukos completes patient enrolment in Phase II trial of GLK-321
Glaukos has completed patient enrolment in its Phase II clinical trial evaluating GLK-321 for the treatment of Demodex blepharitis, using …
Post
-
-
Clariyon’s AI tool boosts sepsis care compliance in hospital study
Clariyon’s artificial intelligence (AI)-powered sepsis care agent has shown potential in improving a physician’s ability to provide quality care to …
-
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy
Absci Corporation has secured $100m in an underwritten offering while reporting positive first-in-human (FIH) data for its lead candidate ABS-201, …
-
First patient dosed in Racura’s HARNESS-1 trial of RC220
Racura Oncology has dosed the first patient in the Phase Ia/b HARNESS-1 trial assessing RC220 in combination with osimertinib for …
-
Anaemia in IgA nephropathy
Glomerulonephritides are conditions in which the primary renal filters (glomeruli) are inflamed, leading to scarring and reduced function. Glomerulonephritides can …
-
Anaemia in IgA nephropathy
Glomerulonephritides are conditions in which the primary renal filters (glomeruli) are inflamed, leading to scarring and reduced function. Glomerulonephritides can …
-
Otsuka’s ADHD drug reduces symptoms in Phase IIIb trial
Otsuka’s daily attention-deficit/hyperactivity disorder (ADHD) candidate has shown benefit in a Phase IIIb trial. In the study (NCT06973577), centanafadine XR 280mg …
-
Ollin Biosciences secures $330m to fund Phase III OLN324 trials
Ollin Biosciences has completed a $330m Series B financing round to support the global Phase III development of its lead …
-
UK bookmarks Spain’s success in race to global clinical trials competitiveness
In recent years, the UK clinical trials sector has faced stiff competition as it looks to build a strong global …
-
Viking Therapeutics commences Phase I trial of VK3019
Viking Therapeutics has commenced a Phase I clinical trial of VK3019, a dual amylin and calcitonin receptor agonist, which is …
-
BIO 2026: How NIH cuts have threatened US competitiveness against China
Funding cuts at US federal agencies have compounded threats to the US’s predominance in global biopharma as an ascendant Chinese …
-
Corxel to advance oral obesity drug to Phase III trials
Corxel Pharmaceuticals’ oral obesity candidate has succeeded in a Phase II trial in the US, teeing it up for a …
-
Ascletis receives FDA clearance for Phase I trial of obesity treatment
Ascletis Pharma has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to initiate a Phase …
-
Pfizer reports topline data from SigVie-002 study for NSCLC
Pfizer has reported topline data from the Phase III SigVie-002 study investigating sigvotatug vedotin in adults with previously treated, locally …
-
Early Biomarkers as Predictors of Nephrology Trial Trajectory
Chronic kidney disease (CKD) and other nephrology conditions are a major global health challenge. With rising prevalence and persistent unmet …
